Current view of the rituximab maintenance in follicular lymphoma

1. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma in patients in the Unites States. J Clin Oncol 2005; 23: 5019–5026.

2. Horning SJ, Rosenberg SA. The natural history of initial untreated low-grade non-Hodgkin’*s lymphomas. N Engl J Med 1984; 311: 1471–75.

3. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’*s lymphomas. Semin Oncol 1993; 20 (suppl 5): 75–88.

4. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with reccurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147.

5. Yuen AR, Kamel OW, Halpern J, Horning S. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13: 1726–1733.

6. Ezdinli EZ, Harrington DP, Kucuk O, et al. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin’*s lymphoma. Cancer 1987; 60: 156–160.

7. Steward WP, Crowther D, McWilliam LJ, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’*s lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988; 61: 441–447.

8. Rohatiner AZS, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223.

9. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’*s lymphoma. Blood 1997; 90: 2188–2195.

10. McLaughlin P, Grillo-López AJ, Link BK, et al Rituximab chimaeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

11. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitises a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharmac. 1997; 12: 177–86.

12. Coiffier B, Lepage E, Briére J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl Med 2002; 346: 235–242.

13. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276.

14. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071.

15. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphoma as compared to CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2005; 106: 3725–3732.

16. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423.

17. Schmitz K, Brugger W, Weiss B, et al. Clonal selection of CD20-negative non-Hodgkin’*s lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999; 106: 571–572.

18. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611–615.

19. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’*s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143.

20. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416–4423.

21. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008.

22. Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301.

23. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 2005; 106: 106a (abstr No 349).

24. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing Therapeutic Benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent Non-Hodgkin’*s lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095.

25. Kahl BS, Williams ME, Hong F, et al. Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab extended schedule or retreatment trial (RESORT). Blood 2007; 118: 1002A (abstr No 3420).

26. Hornberger JC, Reyes C, Shewade A, et al. Cost-effectiveness of rituximab post CVP induction for the treatment of low-grade NHL. Blood 2007; 118: 193B (abstr No 4486).

27. Francisco J, Conde E, Giraldo P, et al. Rituximab maintenance therapy for patients with follicular lymphoma a cost-effective strategy? Haematologica 2007; 92 (S1) 117 (abstr No 0303).

28. Witzens-Harig M, Heiss Ch, Benner A, et al. Quality of life in patients with B-cell lymphoma during maintenance therapy with the anti-CD20 antibody rituximab. Blood 2007; 118: 189B (abstr No 4471).

29. Vidal L, Gafter-Gvili A, Dreyling M, et al. Meta analysis: rituximab as maintenance therapy for patients with follicular lymphoma. Blood 2007; 118: 998A (abstr No 3408).

30. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456–473.

31. Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Weiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11 (suppl 1): 123–126.

32. Fogarty GB, Bayne M, Bedford P, et al. Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol 2006; 18: 155–156.

33. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology 2005; 16: 1675–1682.

34. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’*s lymphoma: a retrospective review. Br J Haematol 2002; 119: 412–16.

35. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98: 1352–1357.

36. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: wals to improve rituximab efficacy. Blood 2004; 104: 2635–2642.

37. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003; 100: 1926–1930.

38. Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Haematol 2003; 82: 585-88.

39. Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematom 2007; 86: 49–57.

40. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932.

41. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466.

42. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’*s lymphoma. J Clin Oncol 1997; 15: 3266–3274.

43. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’*s lymphoma. Ann Oncol 1998; 9: 995-1001.

44. Gordan L, Grow WB, Pusateri A, et al. A phase II trial of individualized pharmacokinetic dosing of rituximab maintenance for patients with CD-20 positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096–1102.